Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

107
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
107
Cancer Survival Analysis01:21

Cancer Survival Analysis

442
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
442
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

219
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
219
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

582
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
582
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

252
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
252
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

121
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
121

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric Oncology Progress and Challenges in Southeast Asia: Strengthening Cancer Care Systems.

Pediatrics·2026
Same author

Artificial Intelligence and the Global Radiotherapy Gap.

JCO global oncology·2026
Same author

Disaggregating Gender Inequality Globally: Health Systems, Gender Inequality, and Female Pan-Cancer Outcomes.

JCO global oncology·2026
Same author

Wearable-Derived Data for Patient Frailty: Extending Hospital Frailty Risk Score While Confronting Bias and Inequities.

Journal of general internal medicine·2026
Same author

Beyond auto-segmentation: the case for planning and dosimetry AI in head and neck radiation oncology.

BMJ oncology·2026
Same author

Impact of Exposure Parameters on Deep Learning Models in Chest Radiography and Implications for Deployment.

Radiology. Artificial intelligence·2026

Related Experiment Video

Updated: Sep 5, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.2K

Developing and Validating Multi-Modal Models for Mortality Prediction in COVID-19 Patients: a Multi-center

Joy Tzung-Yu Wu1, Miguel Ángel Armengol de la Hoz2,3,4, Po-Chih Kuo5,6

  • 1Department of Radiology and Nuclear Medicine, Stanford University, Palo Alto, CA, USA.

Journal of Digital Imaging
|July 5, 2022
PubMed
Summary

Developing accurate COVID-19 mortality prediction models is crucial for healthcare resource allocation. This study presents validated multi-modal machine learning models using electronic health records and chest X-rays, achieving strong predictive performance across diverse clinical settings.

Keywords:
COVID-19Mortality predictionMulti-centerMulti-modal

More Related Videos

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.2K
Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

1.5K

Related Experiment Videos

Last Updated: Sep 5, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.2K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.2K
Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

1.5K

Area of Science:

  • Computational biology and bioinformatics
  • Medical informatics
  • Machine learning in healthcare

Background:

  • The COVID-19 pandemic necessitated the development of predictive models for patient prognostication and resource management.
  • Existing machine learning models for COVID-19 often suffer from methodological limitations and inadequate validation, hindering clinical utility.
  • Multi-modal data integration, combining clinical information and medical imaging, shows promise for improving predictive accuracy.

Purpose of the Study:

  • To develop and validate multi-modal machine learning models for predicting COVID-19 mortality.
  • To assess the performance of these models across diverse, multi-center patient cohorts.
  • To provide a methodological framework and share code for building robust clinical prediction models.

Main Methods:

  • Development of COVID-19 mortality prediction models using retrospective data from Madrid, Spain (N=2547).
  • External validation of models in patient cohorts from New Jersey, USA (N=242) and Seoul, Republic of Korea (N=336).
  • Utilized multi-modal data, integrating structured electronic health records and chest X-ray imaging.

Main Results:

  • Multi-modal models integrating electronic health records and chest X-ray data demonstrated superior 30-day mortality prediction performance across all validation datasets.
  • Achieved areas under the receiver operating characteristic curves of 0.85 (95% CI: 0.83-0.87), 0.76 (95% CI: 0.70-0.82), and 0.95 (95% CI: 0.92-0.98) in the respective cohorts.
  • Model performance varied across clinical settings, highlighting the importance of guided machine learning implementation.

Conclusions:

  • Validated multi-modal machine learning models offer a promising approach for COVID-19 mortality prediction.
  • The integration of clinical and imaging data enhances predictive capabilities in diverse healthcare environments.
  • Adherence to best practices in machine learning development and validation is essential for clinical decision support tools.